BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

SCYNEXIS Europe appoints Geoffrey Sheppard as Head of Radiochemistry

12 January 2004 -- SCYNEXIS Europe Ltd., Ongar, Essex, announced today that Geoffrey Sheppard, PhD has joined the company as Head of Radiochemistry.
Dr. Sheppard is a graduate of Oxford University (Honours Degree and Doctorate in Chemistry). He held senior General Management and Marketing positions at The Radiochemical Centre (which later became Amersham International plc), including an overseas posting in Japan. He was Managing Director of Porton Cambridge Ltd (a UK diagnostics company) and has worked for the Welsh Development Agency, firstly as Representative in Japan and latterly as Executive Director responsible for international marketing and inward investment into Wales. Most recently he has been an advisor to several high technology companies on international business and marketing strategy. He is also a Director of the Asia-Pacific Technology Network.

The appointment of Dr. Sheppard to head its radiochemistry operations underlines the commitment of SCYNEXIS to the radiochemistry area, the company notes. Custom radiolabelling has become a major activity for SCYNEXIS which will be further strengthened by this recruitment.

About SCYNEXIS

SCYNEXIS is a drug discovery and development company headquartered in Research Triangle Park, North Carolina, with its European operations, SCYNEXIS Europe Ltd., located near Cambridge, England. By combining its chemists’ expertise with proprietary KIT™ Kinase Inhibitor Technology, MEDCHEM-FACTORYTM technology and Hit Explorer Operating System (HEOS®), SCYNEXIS provides improved speed and productivity in the chemical validation of drug targets. SCYNEXIS also offers novel hit generation compounds, hit explosion and lead optimization services as well as process optimization, purification and analysis of compound libraries, in vitro ADMET, the production of clinical samples in its GMP facility and radiochemistry synthesis services. For more information, visit www.scynexis.com

Media Contacts:

In the USA: Rick Rountree
(919) 878-1144
rick@rickrountree.com

In Europe: Andy Matthews, O2PR Ltd
+44 (0)1223 309500
andy.matthews@o2pr.co.uk


Business Development Contacts:

In Europe: Dave Roberts
+44(0) 1277 367003
Dave.roberts@scynexis.com

In the USA: Terry Marquardt
(919) 544-8600
terry.marquardt@scynexis.com


 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.